Arcadia Biosciences RKDA
Arcadia Biosciences Q2 FY25: revenue $1.5M, up 11%; diluted EPS −$3.26
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-25-109040
- Document
- 10-Q
Key figures from this report
These are the numbers Arcadia Biosciences reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$1.5M+11% from $1.3M in Q2 FY2410-Q income statement, on EDGAR
- Net income−$4.5M−520% from $1.1M in Q2 FY2410-Q income statement, on EDGAR
- Diluted EPS−$3.26−518% from $0.78 in Q2 FY2410-Q income statement, on EDGAR
- Cash and cash equivalents$1.4M−75% from $5.5M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$2.0MAgainst −$2.5M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 1311 and related industry codes: the same peer list as the financial tables.
- New Concept Energy GBR public float $5M, Jun 30, 2025
- Barnwell Industries BRN public float $5M, Mar 31, 2025, over 18 months old
- Battalion Oil BATL public float $5M, Jun 30, 2025
- Viking Global Technologies CEIN public float $8M, Jun 30, 2025
- Trio Petroleum TPET public float $9M, Apr 30, 2025, over 18 months old
